Lowest-Rated StocksLowest-RatedNASDAQ:PCRX Pacira BioSciences (PCRX) Stock Price, News & Analysis $36.39 0.00 (0.00%) Closing price 10/30/2026 04:00 PM EasternExtended Trading$36.40 +0.01 (+0.01%) As of 10/30/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Pacira BioSciences Stock (NASDAQ:PCRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Pacira BioSciences alerts:Sign Up Key Stats Today's Range$36.38▼$36.4350-Day Range$24.08▼$36.4252-Week Range$18.80▼$36.67Volume737,237 shsAverage Volume2.67 million shsMarket Capitalization$1.45 billionP/E Ratio103.97Dividend YieldN/APrice Target$33.33Consensus RatingHold Company Overview Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain-management and regenerative health solutions. The company’s products are designed to address acute postsurgical pain and osteoarthritis-related pain while supporting efforts to reduce reliance on opioid medications. Pacira’s lead product is EXPAREL, an extended-release formulation of bupivacaine administered by injection for postsurgical pain management. The company also markets ZILRETTA, an extended-release corticosteroid injection indicated for osteoarthritis knee pain, and iovera°, a cryoanalgesia system that uses controlled cooling to temporarily block peripheral nerves and relieve pain. Formerly known as Pacira Pharmaceuticals, the company adopted the Pacira BioSciences name to reflect its broader focus on innovative pain and regenerative-health therapies. Its products are primarily commercialized in the United States and are used across surgical, orthopedic and other healthcare settings.AI Generated. May Contain Errors. Read More Pacira BioSciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScorePCRX MarketRank™: 2.65553671579 of 5 starsPacira BioSciences scored higher than 53% of companies evaluated by MarketBeat, and ranked 510th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.0 / 5Analyst RatingHold Consensus RatingPacira BioSciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 9 hold ratings, and 1 sell rating.Downside RiskPacira BioSciences has a consensus price target of $33.33, representing about 8.4% downside from its current price of $36.39.Amount of Analyst CoveragePacira BioSciences has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Pacira BioSciences' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth27.42% Earnings GrowthEarnings for Pacira BioSciences are expected to grow by 27.42% in the coming year, from $1.86 to $2.37 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pacira BioSciences is 103.97, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.95.Price to Earnings Ratio vs. SectorThe P/E ratio of Pacira BioSciences is 103.97, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 35.76.Price to Book Value per Share RatioPacira BioSciences has a P/B Ratio of 2.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Pacira BioSciences' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted11.42% of the float of Pacira BioSciences has been sold short.Short Interest Ratio / Days to CoverPacira BioSciences has a short interest ratio ("days to cover") of 1.08, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pacira BioSciences has recently decreased by 47.25%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPacira BioSciences does not currently pay a dividend.Dividend GrowthPacira BioSciences does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.66 News SentimentPacira BioSciences has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Pacira BioSciences this week, compared to 5 articles on an average week.Search Interest3 people have searched for PCRX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Pacira BioSciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $288,539.00 in company stock.Percentage Held by Insiders6.40% of the stock of Pacira BioSciences is held by insiders.Percentage Held by Institutions99.73% of the stock of Pacira BioSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Pacira BioSciences' insider trading history. Receive PCRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PCRX Stock News HeadlinesPCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its ShareholdersOctober 31 at 7:10 AM | businesswire.comViatris Begins Cash Tender Offer To Acquire Pacira At $36.50 Per Share; Stock DownOctober 30 at 9:17 PM | rttnews.comThe 401k Email 70 Million Investors Might DeleteAn email announcing a new 401k investment option is headed to roughly 70 million inboxes. Most recipients will delete it without a second look. Larry Benedict says that would be a mistake. He calls this the decade's biggest opportunity and is naming the one ticker to watch before it arrives. Watch his free breakdown now.November 1 at 1:00 AM | Brownstone Research (Ad)Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc.October 30 at 8:40 AM | prnewswire.comPacira BioSciences (PCRX) reports next week: Wall Street expects earnings growthOctober 29 at 2:06 PM | msn.comETFs Are Net Sellers of Pacira BioSciences (PCRX) on Oct. 22October 26, 2026 | finance.yahoo.comPacira BioSciences (PCRX) Stock Gets Fair Value Boost After Viatris Deal FramingOctober 23, 2026 | uk.finance.yahoo.comPacira BioSciences (NASDAQ:PCRX) SVP Lauren Riker Sells 6,000 Shares of StockOctober 10, 2026 | insidertrades.comSee More Headlines PCRX Stock Analysis - Frequently Asked Questions How have PCRX shares performed this year? Pacira BioSciences' stock was trading at $25.88 on January 1st, 2026. Since then, PCRX shares have increased by 40.6% and is now trading at $36.39. How were Pacira BioSciences' earnings last quarter? Pacira BioSciences, Inc. (NASDAQ:PCRX) released its earnings results on Tuesday, August, 4th. The company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.08. The firm's revenue was up 6.2% on a year-over-year basis. Read the conference call transcript. When did Pacira BioSciences IPO? Pacira BioSciences (PCRX) raised $64 million in an initial public offering (IPO) on Wednesday, February 2nd 2011. The company issued 4,250,000 shares at $14.00-$16.00 per share. Who are Pacira BioSciences' major shareholders? Pacira BioSciences' top institutional investors include Bridge City Capital LLC (0.88%), Robeco Institutional Asset Management B.V. (0.41%), Profund Advisors LLC (0.14%) and VIRGINIA RETIREMENT SYSTEMS ET Al (0.13%). Insiders that own company stock include Jonathan Slonin, Daryl Gaugler, Frank D Lee, Shawn Cross, Kristen Williams, Lauren Riker, Mark Froimson and Marcelo Bigal. View institutional ownership trends. How do I buy shares of Pacira BioSciences? Shares of PCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pacira BioSciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pacira BioSciences investors own include Gilead Sciences (GILD), Micron Technology (MU), Tesla (TSLA), Bristol Myers Squibb (BMY), NVIDIA (NVDA), Palo Alto Networks (PANW) and Alphabet (GOOG). Company Calendar Last Earnings8/04/2026Today11/01/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (7m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 PCRX's financial health is in the Green zone, according to TradeSmith. PCRX has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:PCRX CIK1396814 Webwww.pacira.com Phone(813) 553-6680Fax302-655-5049Employees829Year Founded2006Price Target and Rating Average Price Target for Pacira BioSciences$33.33 High Price Target$36.50 Low Price Target$25.00 Potential Upside/Downside-8.4%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)$0.35 Trailing P/E Ratio103.97 Forward P/E Ratio19.56 P/E GrowthN/ANet Income$7.03 million Net Margins1.96% Pretax Margin2.37% Return on Equity9.68% Return on Assets5.30% Debt Debt-to-Equity Ratio0.54 Current Ratio5.04 Quick Ratio3.94 Sales & Book Value Annual Sales$726.41 million Price / Sales2.00 Cash Flow$3.86 per share Price / Cash Flow9.43 Book Value$16.11 per share Price / Book2.26Miscellaneous Outstanding Shares39,860,000Free Float37,311,000Market Cap$1.45 billion OptionableOptionable Beta0.25 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:PCRX) was last updated on 10/30/2026 by MarketBeat.com Staff. From Our PartnersThe most dangerous moment in a financial crisisDr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. ...Weiss Ratings | SponsoredThe 401k Email 70 Million Investors Might DeleteAn email announcing a new 401k investment option is headed to roughly 70 million inboxes. Most recipients will...Brownstone Research | SponsoredYour free stock pick for todayElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredCigar Lake Flooded Again Uranium Supply Shock RepeatsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredDoes your nest egg have an expiration date?A $250,000 nest egg growing at 5% a year and paying out $2,500 a month runs dry in just over a decade. Start w...Investors Alley | SponsoredThe Claude AI company doubled in value... you missed itIn May, Anthropic raised money at a $965 billion valuation. Now, ahead of its IPO, investors are reportedly di...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacira BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pacira BioSciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PCRX Stock Alerts